Transition Metal Based Anticancer Drugs

Author(s): K. Benjamin Garbutcheon-Singh, Maxine P. Grant, Benjamin W. Harper, Anwen M. Krause-Heuer, Madhura Manohar, Nikita Orkey, Janice R. Aldrich-Wright

Journal Name: Current Topics in Medicinal Chemistry

Volume 11 , Issue 5 , 2011

Become EABM
Become Reviewer


With an ageing baby-boomer population in the Western World, cancer is becoming a significant cause of death. The prevalence of cancer and all associated costs, both in human and financial terms, drives the search for new therapeutic drugs and treatments. Platinum anticancer agents, such as cisplatin have been highly successful but there are several disadvantages associated with their use. What is needed are new compounds with different mechanisms of action and resistance profiles. What needs to be recognised is that there are many other metals in the periodic table with therapeutic potential. Here we have highlighted metal complexes with activity and illustrate the different approaches to the design of anticancer complexes.

Keywords: Platinum, ruthenium, copper, palladium, titanium, vanadium, cobalt, gold, Cancer, platinum complexes, drug design, Electrostatic binding, Carboplatin, maximum

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [521 - 542]
Pages: 22
DOI: 10.2174/156802611794785226
Price: $65

Article Metrics

PDF: 30